Witnessing the stock’s movement on the chart, on Thursday, Revance Therapeutics Inc (NASDAQ: RVNC) remained unchanged to $3.07, before settling in for the price of $3.07 at the close. Taking a more long-term approach, RVNC posted a 52-week range of $2.30-$9.74.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 815.27%. Meanwhile, its Annual Earning per share during the time was 0.57%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 42.40%. This publicly-traded company’s shares outstanding now amounts to $104.90 million, simultaneously with a float of $95.30 million. The organization now has a market capitalization sitting at $320.48 million. At the time of writing, stock’s 50-day Moving Average stood at $4.41, while the 200-day Moving Average is $4.38.
Revance Therapeutics Inc (RVNC) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Revance Therapeutics Inc’s current insider ownership accounts for 8.71%, in contrast to 80.74% institutional ownership. According to the most recent insider trade that took place on Nov 18 ’24, this organization’s CMO & Global Therapeutics Lead sold 3,908 shares at the rate of 4.17, making the entire transaction reach 16,296 in total value, affecting insider ownership by 104,945. Preceding that transaction, on Apr 16 ’24, Company’s Chief Commercial Officer sold 2,392 for 3.80, making the whole transaction’s value amount to 9,096. This particular insider is now the holder of 114,864 in total.
Revance Therapeutics Inc (RVNC) Earnings and Revenue Records
Revance Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 42.40% and is forecasted to reach -0.69 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 11.60% through the next 5 years, which can be compared against the 0.57% growth it accomplished over the previous five years trading on the market.
Revance Therapeutics Inc (NASDAQ: RVNC) Trading Performance Indicators
Let’s observe the current performance indicators for Revance Therapeutics Inc (RVNC). It’s Quick Ratio in the last reported quarter now stands at 3.05. The Stock has managed to achieve an average true range (ATR) of 0.21. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 1.30.
In the same vein, RVNC’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.92, a figure that is expected to reach -0.25 in the next quarter, and analysts are predicting that it will be -0.69 at the market close of one year from today.
Technical Analysis of Revance Therapeutics Inc (RVNC)
Going through the that latest performance of [Revance Therapeutics Inc, RVNC]. Its last 5-days volume of 3.33 million indicated improvement to the volume of 2.82 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 23.90% While, its Average True Range was 0.16.
Raw Stochastic average of Revance Therapeutics Inc (RVNC) in the period of the previous 100 days is set at 8.09%, which indicates a major rise in contrast to 5.17% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 106.82% that was lower than 147.21% volatility it exhibited in the past 100-days period.
